UBS: Resumes Coverage on Regeneron Pharmaceuticals (REGN.US) with "Buy" Rating, Undervalues the Potential of Blockbuster Drug Dupixent

智通财经2026/10/15 06:46

Show original

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Zhihu Finance APP has learned that UBS has resumed coverage of Regeneron Pharmaceuticals (REGN.US) with a “Buy” rating and a target price of $978, which is about 30% higher than the latest closing price. Previously, the bank had assigned a “Neutral” rating to the stock.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

UBS: Resumes Coverage on Regeneron Pharmaceuticals (REGN.US) with "Buy" Rating, Undervalues the Potential of Blockbuster Drug Dupixent

You may also like

Crypto prices